(Note: For PDF File Swipe To The End Of Article)
Category: Neurology | Medical Education | Nursing | Healthcare Awareness
1. Introduction: Understanding Parkinson’s Disease
Imagine waking up one morning and noticing that your hand shakes slightly while resting on your lap. At first, you may think it is fatigue, stress, or simply a part of getting older. Over time, you may notice that your handwriting has become smaller, your steps have become shorter, your movements feel slower, and everyday tasks take longer than they used to.
For some people, these changes may be early signs of Parkinson’s disease, a progressive neurological disorder that affects movement and can also influence sleep, mood, digestion, thinking, and many other aspects of daily life.
Parkinson’s disease is more than a condition associated with trembling hands. It is a complex disorder involving changes in the brain's movement-control systems and, in many people, other nervous system functions. Its symptoms vary considerably from person to person. Some individuals experience prominent tremors, while others mainly struggle with stiffness, slowness, balance difficulties, fatigue, or non-motor symptoms.
Although Parkinson’s disease currently has no established cure, significant progress has been made in understanding and managing it. Medicines, exercise, physical therapy, occupational therapy, speech therapy, psychological support, and selected surgical treatments can help many people maintain independence and improve their quality of life.
Early recognition is important because symptoms that appear minor at first may affect daily activities as the condition progresses. Understanding the disease also helps families replace fear and misconceptions with informed decisions, compassion, and practical support.
This article provides a detailed overview of Parkinson’s disease, including its definition, causes, brain changes, risk factors, symptoms, diagnosis, treatment options, complications, nursing care, and the latest directions in research.
2. What Is Parkinson’s Disease?
Parkinson’s disease, commonly abbreviated as PD, is a progressive neurodegenerative disorder that primarily affects the nervous system responsible for controlling movement.
The word neurodegenerative refers to a process in which nerve cells become damaged or are lost over time. In Parkinson’s disease, a particularly important group of nerve cells produces a chemical messenger called dopamine.
Dopamine helps the brain coordinate smooth, controlled, purposeful movements. When dopamine-producing neurons become damaged, the brain's movement-control circuits do not function normally. This contributes to symptoms such as slow movement, stiffness, and tremor.
Parkinson’s disease can also affect systems involved in sleep, mood, motivation, digestion, blood pressure, and thinking. These symptoms may appear before, alongside, or after noticeable movement problems.
The condition usually develops gradually. Its progression is different for each individual, and no two people necessarily experience the same symptoms, severity, or rate of change.
Parkinson’s disease is not contagious. It is not simply a normal part of aging, although advancing age is an important risk factor. It can also occur in younger adults, including people diagnosed before age 50.
3. A Brief History of Parkinson’s Disease
Parkinson’s disease is named after James Parkinson, an English physician who described the condition in 1817 in a work titled An Essay on the Shaking Palsy.
He observed several people who experienced characteristic changes in movement, including shaking, altered posture, and difficulty walking. His description helped establish a recognizable clinical condition that later became known as Parkinson’s disease.
Over the following centuries, scientists learned much more about the brain structures involved in movement. Research established the importance of dopamine and identified the loss of dopamine-producing neurons in a brain region called the substantia nigra.
These discoveries transformed medical understanding of the disorder and contributed to the development of levodopa, one of the most important medicines used to treat Parkinson’s disease.
Today, researchers continue to investigate genetic influences, environmental exposures, abnormal protein accumulation, biomarkers, and therapies that may eventually modify the underlying disease process.
4. Anatomy of the Brain: How Normal Movement Works
To understand Parkinson’s disease, it helps to know how the brain controls movement.
4.1 The brain
The brain coordinates movement, sensation, memory, emotions, and many automatic body functions.
Walking, writing, reaching for a cup, buttoning a shirt, and turning around require communication between multiple brain regions, the spinal cord, nerves, and muscles.
Movement normally occurs through coordinated signals rather than through one isolated brain structure.
4.2 Basal ganglia
The basal ganglia are a group of interconnected brain structures involved in selecting, initiating, and regulating movements.
They help the brain decide which movements to perform, how much movement is needed, and how competing movements should be controlled.
When the basal ganglia circuits function properly, movements can be smooth, efficient, and appropriately timed.
4.3 Substantia nigra
The substantia nigra is a region located deep within the brain. A portion of this region contains neurons that produce dopamine and send signals to other movement-related structures.
In Parkinson’s disease, many of these dopamine-producing neurons are progressively lost or become dysfunctional.
As dopamine signaling decreases, movement-control circuits become less effective, contributing to the characteristic motor symptoms.
4.4 Dopamine
Dopamine is a neurotransmitter, meaning a chemical messenger that helps nerve cells communicate.
In the movement system, dopamine helps regulate the activity of circuits that facilitate desired movements and suppress unwanted movement patterns.
When dopamine becomes insufficient, a person may experience slowness, stiffness, reduced automatic movement, and other symptoms associated with Parkinson’s disease.
Dopamine also participates in motivation, reward, attention, and other brain functions. This helps explain why Parkinson’s disease may affect more than physical movement.
4.5 Other brain chemicals
Although dopamine is central to Parkinson’s disease, other neurotransmitter systems may also be affected.
Changes involving noradrenaline, serotonin, acetylcholine, and other signaling systems may contribute to symptoms such as blood pressure changes, sleep problems, mood changes, and cognitive difficulties.
This is one reason why treatment requires more than simply replacing dopamine.
5. What Happens in the Brain During Parkinson’s Disease?
Parkinson’s disease develops through complex biological processes that are not yet fully understood.
5.1 Loss of dopamine-producing neurons
One of the defining features is the progressive loss of dopamine-producing neurons in the substantia nigra.
As dopamine signaling declines, movement-control circuits become less efficient. The person may find it increasingly difficult to initiate movements, maintain a normal walking rhythm, or perform tasks that previously required little conscious effort.
Symptoms often become noticeable only after substantial changes have occurred in the brain.
5.2 Alpha-synuclein and Lewy bodies
Another important feature is the abnormal accumulation of a protein called alpha-synuclein.
In many people with Parkinson’s disease, abnormal deposits of this protein form structures known as Lewy bodies inside nerve cells.
Researchers are investigating how alpha-synuclein changes, spreads, and contributes to neuronal injury. However, the precise sequence of events and the role of these deposits are still being studied.
Lewy bodies are an important pathological feature, but their presence does not by itself explain every aspect of the disease.
5.3 Oxidative stress
Oxidative stress occurs when the production of harmful reactive molecules exceeds the body's ability to neutralize them.
Researchers have investigated whether oxidative stress contributes to damage in dopamine-producing neurons. It is considered one possible part of a larger biological process rather than a complete explanation for Parkinson’s disease.
5.4 Mitochondrial dysfunction
Mitochondria are structures within cells that help produce energy.
When mitochondrial function is impaired, neurons may struggle to meet their energy requirements and may become more vulnerable to damage.
Mitochondrial dysfunction has been implicated in Parkinson’s disease, particularly in research involving certain genetic forms of the condition.
5.5 Neuroinflammation
Neuroinflammation refers to inflammatory activity within the nervous system.
Scientists are studying how immune cells in the brain interact with damaged neurons and abnormal proteins. These processes may contribute to disease progression, although their exact role remains under investigation.
Important: Parkinson’s disease does not result from one single confirmed cause. It is likely to arise through interactions among several biological mechanisms, genetic influences, and environmental factors.
6. Causes and Risk Factors of Parkinson’s Disease
The exact cause of Parkinson’s disease remains unknown in most cases. Researchers believe that a combination of genetic susceptibility, aging, environmental exposures, and biological processes contributes to its development.
6.1 Increasing age
Age is the strongest established risk factor for Parkinson’s disease. The condition most commonly develops in later adulthood, although younger-onset forms occur.
Aging is associated with changes in cellular repair, protein handling, and other biological processes that may influence vulnerability to neurodegeneration.
However, Parkinson’s disease is not an inevitable consequence of aging. Most older adults do not develop the condition.
6.2 Genetic factors
Certain genetic variations can increase the risk of Parkinson’s disease.
Genes that have been studied include LRRK2, GBA1, SNCA, PRKN, PINK1, and PARK7, among others.
Some variants are associated with inherited forms of the condition, while others may increase susceptibility without directly determining whether a person will develop the disease.
A family history can be relevant, but many people with Parkinson’s disease have no known affected relative.
Genetic counseling may be helpful for selected individuals who have a strong family history, early-onset disease, or a specific reason to consider genetic testing.
6.3 Environmental exposures
Researchers have investigated associations between Parkinson’s disease and certain environmental exposures, including some pesticides and industrial chemicals.
Some studies have found associations, but the relationship is complex. Exposure does not mean that a person will necessarily develop Parkinson’s disease, and not every suspected environmental factor has been conclusively established as a cause.
6.4 Head injuries
Some research has found an association between significant head injury and an increased risk of Parkinson’s disease.
However, a history of head injury does not establish that it caused the condition in a particular individual.
6.5 Sex-related differences
Parkinson’s disease is diagnosed more frequently in men than in women in many populations. Researchers are studying the biological and environmental factors that may contribute to this difference.
6.6 Other possible influences
Scientists continue to investigate the roles of immune activity, metabolic processes, gut-related mechanisms, and other factors.
Some findings are promising, but many remain under investigation and should not be treated as established explanations for individual cases.
6.7 Can Parkinson’s disease be prevented?
There is currently no proven method that guarantees prevention of Parkinson’s disease.
Regular physical activity, a balanced diet, adequate sleep, and avoidance of harmful environmental exposures where possible are reasonable health practices. However, none can guarantee that the disease will not develop.
People should be cautious about supplements or commercial products claiming to prevent Parkinson’s disease or stop its progression without strong clinical evidence.
7. Types of Parkinson’s Disease and Parkinsonism
The terms Parkinson’s disease and parkinsonism are related but do not mean exactly the same thing.
7.1 Idiopathic Parkinson’s disease
Idiopathic means that the precise cause is not identified.
Most people diagnosed with Parkinson’s disease have an idiopathic form, although genetic and environmental factors may contribute.
7.2 Young-onset Parkinson’s disease
Young-onset Parkinson’s disease refers to disease beginning at a younger age, often before 50.
Symptoms may affect education, employment, family responsibilities, and long-term financial planning. Genetic influences may be more relevant in some younger patients.
7.3 Familial Parkinson’s disease
In some families, inherited genetic variants contribute to Parkinson’s disease risk.
The inheritance pattern and likelihood of developing disease depend on the particular gene and variant. A genetic finding does not always predict the age of onset or severity.
7.4 Secondary parkinsonism
Parkinsonism is a group of movement abnormalities that can include slowness, stiffness, and tremor.
Similar symptoms may result from certain medicines, vascular disease, brain injuries, or other conditions.
For example, dopamine-blocking medicines used for some psychiatric or gastrointestinal conditions can cause parkinsonian symptoms in susceptible individuals.
A clinician may review medications and other possible causes when evaluating a person with movement changes. Prescribed medication should not be stopped abruptly without medical advice.
7.5 Atypical parkinsonian disorders
Other neurological disorders can produce symptoms that resemble Parkinson’s disease. These include multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, and dementia with Lewy bodies.
They may have additional clinical features, different patterns of progression, or different responses to treatment.
Distinguishing these conditions is important because prognosis and management can differ.
8. The Four Major Motor Symptoms of Parkinson’s Disease
Parkinson’s disease is commonly associated with four important movement-related features: tremor, rigidity, bradykinesia, and postural instability.
Not everyone develops all four, and their severity varies.
8.1 Tremor
A tremor is an involuntary rhythmic movement.
In Parkinson’s disease, a characteristic tremor often appears when a limb is resting and may become less noticeable during purposeful movement. It frequently begins in one hand but can also affect a foot, jaw, or other body part.
A typical hand tremor may resemble a repeated rubbing movement between the thumb and index finger, sometimes described as a “pill-rolling” tremor.
Tremor may become more noticeable during stress or fatigue and often decreases during sleep.
However, not every person with Parkinson’s disease develops a prominent tremor. Some people mainly experience stiffness and slowness.
Tremor can also occur in other conditions, including essential tremor, medication-related disorders, anxiety, and metabolic conditions. A tremor alone does not establish a diagnosis of Parkinson’s disease.
8.2 Rigidity
Rigidity refers to increased resistance when a relaxed limb is moved by another person.
The muscles may feel unusually stiff or tight. A person may report aching, discomfort, or difficulty moving an arm or leg freely.
Rigidity can affect the shoulders, neck, trunk, and limbs. It may contribute to stooped posture and reduced arm swing during walking.
Clinicians sometimes describe rigidity as “lead-pipe” resistance or “cogwheel” resistance, depending on how it feels during examination.
8.3 Bradykinesia
Bradykinesia means slowness of movement. It is one of the most important clinical features of Parkinson’s disease.
It may affect everyday activities in subtle ways at first.
Examples include:
- Taking longer to button a shirt.
- Moving more slowly while eating.
- Having difficulty starting a movement.
- Taking longer to rise from a chair.
- Making smaller movements when writing.
- Showing fewer facial expressions.
- Walking with shorter steps.
Bradykinesia may also cause repetitive movements to become progressively smaller or slower.
A person may understand exactly what they want to do but find that the body does not respond as quickly as expected.
8.4 Postural instability and balance problems
Postural instability refers to impaired balance and difficulty maintaining stability during movement.
It can increase the risk of falls, particularly when turning, stepping backward, or walking on uneven surfaces.
Balance difficulties often become more prominent as the disease progresses, although the timing varies.
Early, frequent falls can also suggest that another neurological condition may need to be considered.
9. Other Movement-Related Symptoms
Parkinson’s disease can produce several additional changes in movement and posture.
9.1 Shuffling gait
A person may begin taking short steps, dragging the feet, or walking with reduced arm swing.
The walking pattern may become less fluid, making it difficult to navigate crowded spaces or walk on uneven ground.
9.2 Freezing of gait
Freezing occurs when a person temporarily feels unable to move their feet forward despite intending to walk.
It may happen when starting to walk, turning, passing through a narrow doorway, or approaching a destination.
Freezing can be frightening because it increases the risk of falls.
Physical therapists may teach cueing strategies, such as stepping toward a visual target, following a rhythm, or using a deliberate weight shift. These strategies should be practiced safely and tailored to the individual.
9.3 Festination
Festination is a walking pattern in which steps become increasingly short and rapid, sometimes with the body leaning forward.
The person may find it difficult to slow down or stop.
Festination requires attention because it can contribute to falls.
9.4 Reduced facial expression
Some people develop a reduced range of facial movement, sometimes called hypomimia or “masked face.”
Others may mistakenly interpret this as sadness, anger, or lack of interest. In reality, reduced facial expression may reflect changes in automatic movement rather than the person's actual emotional state.
9.5 Changes in handwriting
Handwriting may become smaller and more crowded, a change known as micrographia.
The person may begin writing at a normal size but gradually produce smaller letters within the same line.
9.6 Changes in speech
Speech may become softer, less expressive, or more difficult to understand.
Some people speak rapidly, while others have difficulty projecting their voice. Speech-language therapy can help address these problems.
9.7 Difficulty with fine motor tasks
Activities such as fastening buttons, handling coins, using utensils, shaving, or tying shoelaces may become more difficult.
Occupational therapy can help identify practical adaptations and strategies to maintain independence.
10. Non-Motor Symptoms: The Less Visible Side of Parkinson’s Disease
Parkinson’s disease affects more than movement. Non-motor symptoms can be present early and may have a substantial effect on quality of life.
10.1 Loss of smell
A reduced sense of smell, known as hyposmia, may occur years before obvious movement symptoms.
It is not specific to Parkinson’s disease and can also occur with other neurological conditions, infections, nasal disorders, and aging.
10.2 Constipation
Constipation is common in Parkinson’s disease and may appear before motor symptoms.
Changes in the nervous system can affect intestinal movement. Reduced physical activity, dietary factors, and some medications may contribute as well.
Management may include appropriate fluid intake, fiber, physical activity, and clinician-recommended treatments.
10.3 Sleep disorders
Sleep problems may include difficulty falling asleep, waking frequently, daytime sleepiness, insomnia, or unusual movements during sleep.
Some people experience REM sleep behavior disorder, in which they physically act out dreams because normal muscle relaxation during dream sleep is reduced.
Vivid dream enactment may cause injury to the individual or their bed partner. It should be discussed with a healthcare professional.
10.4 Depression
Depression can occur in people with Parkinson’s disease and may involve persistent sadness, loss of interest, reduced motivation, sleep changes, or feelings of hopelessness.
These symptoms are not a personal failure or a sign of weakness.
Depression is treatable, and appropriate support may include psychological therapy, medication, social support, and management of contributing symptoms.
10.5 Anxiety
Anxiety may appear as excessive worry, fear of falling, discomfort in unfamiliar settings, or episodes of intense distress.
For some individuals, anxiety may fluctuate with medication timing or changes in movement symptoms.
Recognizing and treating anxiety can improve daily functioning.
10.6 Fatigue
Fatigue is a feeling of exhaustion that may not improve fully with rest.
It can arise from the disease itself, sleep disturbances, depression, medication effects, or the additional effort required to complete everyday tasks.
A clinician may assess treatable contributors rather than assuming fatigue is an unavoidable part of the condition.
10.7 Autonomic dysfunction
The autonomic nervous system regulates functions such as blood pressure, digestion, sweating, bladder activity, and aspects of sexual function.
Parkinson’s disease may affect this system.
Possible symptoms include dizziness when standing, constipation, excessive sweating, urinary urgency, and sexual difficulties.
10.8 Cognitive changes
Some people develop difficulty with attention, planning, multitasking, processing information, or remembering details.
Cognitive changes vary widely and do not necessarily mean that a person has dementia.
If thinking or memory problems interfere with everyday activities, clinical assessment can help identify the cause and appropriate support.
10.9 Hallucinations
Some people with Parkinson’s disease experience hallucinations, such as seeing people, animals, or objects that are not present.
Hallucinations may be associated with the disease, medication effects, sleep disruption, or other medical problems.
New or sudden hallucinations, especially with confusion or fever, require prompt medical evaluation rather than being automatically attributed to Parkinson’s disease.
11. Early Warning Signs of Parkinson’s Disease
Parkinson’s disease usually begins gradually. Early changes may be subtle and can easily be attributed to aging, stress, arthritis, or other conditions.
Possible early signs include:
- A resting tremor in one hand or another limb.
- Reduced arm swing while walking.
- Smaller handwriting.
- Slower movements during routine activities.
- Persistent stiffness that affects movement.
- Reduced facial expression.
- A softer or less expressive voice.
- Reduced sense of smell.
- Constipation that develops without an obvious explanation.
- Sleep behavior changes, such as acting out dreams.
- Changes in posture or walking pattern.
- Dizziness when standing.
These symptoms are not proof of Parkinson’s disease. Many have other explanations, and isolated symptoms such as constipation or loss of smell are common in the general population.
A medical assessment is appropriate when movement changes persist, worsen, or interfere with everyday activities.
12. Stages and Progression of Parkinson’s Disease
Parkinson’s disease is progressive, but its course is not identical for everyone.
Clinicians sometimes use the Hoehn and Yahr scale to describe the severity of motor symptoms. This is a useful framework, but it does not capture every aspect of the disease, especially non-motor symptoms.
Stage 1: Mild, mainly one-sided symptoms
Symptoms are generally mild and may affect one side of the body more than the other.
A person may notice a tremor, subtle stiffness, or reduced arm swing while continuing most everyday activities independently.
Stage 2: Symptoms on both sides
Symptoms affect both sides of the body, although one side may remain more affected.
Movement becomes slower, and changes in posture or walking may become more noticeable. Many people remain independent, although daily tasks may require more time.
Stage 3: Balance difficulties
Balance impairment becomes more evident, and falls may become more likely.
A person may still perform many daily activities independently but may benefit from physical therapy, home safety changes, and additional support.
Stage 4: Significant disability
Movement difficulties become more severe and may substantially limit independence.
A person may need assistance with walking, dressing, bathing, or other daily activities. Some people can still stand or walk with assistance or an appropriate mobility aid.
Stage 5: Advanced disability
In the most advanced stage, a person may require a wheelchair or spend much of the day in bed and need substantial help with daily care.
Not everyone progresses through the stages in the same way or at the same rate.
Important: These stages are descriptive, not a timetable. They cannot predict exactly how a particular person's symptoms will develop.
13. Diagnosis of Parkinson’s Disease
There is currently no single routine test that definitively diagnoses Parkinson’s disease in every patient. Diagnosis is primarily clinical, based on medical history and neurological examination.
13.1 Medical history
The clinician asks about the onset, duration, and progression of symptoms.
Important questions may include:
- When did the tremor or slowness begin?
- Did symptoms start on one side?
- Are there changes in walking or balance?
- Have there been falls?
- Are there sleep, bowel, bladder, or mood symptoms?
- Which medicines does the person take?
- Is there a family history of Parkinson’s disease or related disorders?
The answers help identify patterns that support Parkinson’s disease or suggest an alternative explanation.
13.2 Neurological examination
The clinician evaluates movement, muscle tone, coordination, posture, walking, balance, facial expression, and other neurological functions.
An important diagnostic feature is bradykinesia, together with tremor or rigidity in a compatible clinical pattern.
The clinician may ask the person to tap their fingers repeatedly, open and close their hands, stand from a chair, walk, turn, and perform other movements.
The examination may reveal slowness, reduced movement amplitude, stiffness, resting tremor, or changes in gait.
13.3 Response to levodopa
Levodopa is a medicine that the brain can convert into dopamine.
A clear improvement in characteristic motor symptoms after levodopa can support a diagnosis of Parkinson’s disease, although response is not a perfect diagnostic test.
Some other disorders may show partial improvement, and not every person with Parkinson’s disease responds identically.
A medication trial should be conducted under appropriate clinical supervision.
13.4 Blood tests
Blood tests do not ordinarily confirm Parkinson’s disease.
They may be used to investigate alternative causes of symptoms, such as thyroid disorders, vitamin deficiencies, metabolic abnormalities, or other conditions suggested by the clinical picture.
13.5 MRI of the brain
Magnetic resonance imaging, or MRI, may be used when the clinician needs to assess other causes of parkinsonism.
It can help identify certain structural or vascular abnormalities, but a routine MRI does not usually establish Parkinson’s disease by itself.
13.6 Dopamine transporter imaging
A dopamine transporter scan, often called a DaTscan, may help identify loss of dopamine transporter activity in the brain when the diagnosis is uncertain.
However, it does not reliably distinguish Parkinson’s disease from every other disorder that causes degeneration of the dopamine system.
It is an additional tool, not a replacement for clinical assessment.
13.7 Genetic testing
Genetic testing may be considered in selected circumstances, including younger-onset disease, a strong family history, or situations where the result could influence care or research participation.
The usefulness of testing depends on the clinical context and the specific genes examined. Genetic counseling can help explain the limitations and implications of the results.
13.8 Biomarker research
Researchers are investigating tests that detect biological changes associated with Parkinson’s disease, including alpha-synuclein-related markers in certain tissues or body fluids.
Some tests may support diagnosis in selected clinical settings, but availability, interpretation, and ability to distinguish Parkinson’s disease from related disorders vary.
A positive biomarker result should be interpreted by a qualified clinician alongside the clinical findings.
14. Conditions That Can Mimic Parkinson’s Disease
Several disorders can produce symptoms resembling Parkinson’s disease.
14.1 Essential tremor
Essential tremor commonly causes shaking during activities such as writing, drinking from a cup, or holding an object.
It differs from the classic resting tremor associated with Parkinson’s disease, although the two conditions can sometimes be difficult to distinguish.
14.2 Drug-induced parkinsonism
Certain medicines can cause stiffness, slowness, and tremor by interfering with dopamine signaling.
The clinician reviews medication history and considers whether the symptoms began after a medicine was introduced or its dose changed.
Prescribed medicines should not be stopped without medical advice.
14.3 Vascular parkinsonism
Changes associated with cerebrovascular disease can produce gait and movement problems resembling parkinsonism.
The pattern of symptoms, medical history, and brain imaging may help distinguish it from Parkinson’s disease.
14.4 Multiple system atrophy
Multiple system atrophy is a progressive neurological disorder that can produce parkinsonism alongside significant autonomic problems, such as severe blood pressure changes or urinary dysfunction.
Its clinical course and response to treatment may differ from typical Parkinson’s disease.
14.5 Progressive supranuclear palsy
Progressive supranuclear palsy may cause stiffness, walking difficulties, falls, and problems moving the eyes vertically.
Early prominent falls or certain eye-movement abnormalities may suggest this or another diagnosis rather than typical Parkinson’s disease.
14.6 Dementia with Lewy bodies
Dementia with Lewy bodies can involve cognitive changes, visual hallucinations, fluctuations in alertness, sleep disturbances, and parkinsonian movement symptoms.
The timing of cognitive and motor symptoms helps clinicians distinguish this condition from Parkinson’s disease dementia.
15. Treatment of Parkinson’s Disease: An Overview
There is currently no established cure for Parkinson’s disease, and available treatments do not reliably stop or reverse the underlying neurodegenerative process.
However, treatment can substantially improve symptoms and quality of life.
The best plan depends on the individual's symptoms, age, general health, daily activities, work, preferences, medication response, and potential side effects.
Treatment may include medication, exercise, rehabilitation, psychological support, dietary changes, and selected surgical or device-assisted therapies.
A neurologist, ideally one with experience in movement disorders, can help develop and adjust the treatment plan.
16. Medications Used to Treat Parkinson’s Disease
16.1 Levodopa
Levodopa is one of the most effective medicines for many movement symptoms of Parkinson’s disease.
It crosses into the brain and is converted into dopamine, helping restore dopamine signaling.
Levodopa is commonly combined with carbidopa. Carbidopa reduces the conversion of levodopa outside the brain, allowing more levodopa to reach the brain and helping reduce certain side effects.
The combination is often called carbidopa-levodopa or levodopa-carbidopa, depending on local naming conventions.
Benefits may include improved slowness, stiffness, and tremor. However, response varies, and some symptoms—especially certain balance, speech, or cognitive difficulties—may respond less well.
Potential side effects include nausea, dizziness, low blood pressure, involuntary movements, and, in some people, hallucinations or confusion.
Medication should be individualized. Patients should not abruptly stop long-term Parkinson’s medicines because sudden withdrawal can cause serious complications.
16.2 Dopamine agonists
Dopamine agonists stimulate dopamine receptors, imitating some of dopamine's effects.
Examples include pramipexole, ropinirole, and rotigotine.
These medicines may be used in selected patients, depending on symptoms and other factors.
Possible adverse effects include nausea, dizziness, sleepiness, hallucinations, swelling, and impulse-control problems.
Impulse-control problems may involve gambling, compulsive shopping, binge eating, or increased sexual urges. Patients and caregivers should report concerning behavioral changes promptly.
16.3 MAO-B inhibitors
Monoamine oxidase B inhibitors reduce the breakdown of dopamine in the brain.
Examples include rasagiline, selegiline, and safinamide.
They may provide symptom relief in selected patients, either alone in particular circumstances or alongside other Parkinson’s medicines.
Possible side effects and medication interactions should be reviewed by a clinician or pharmacist.
16.4 COMT inhibitors
Catechol-O-methyltransferase inhibitors reduce the breakdown of levodopa and can extend its effect in selected patients.
Examples include entacapone and opicapone. Tolcapone is another drug in this class but has important liver-related safety considerations and requires particular caution.
These medicines are commonly considered when levodopa's effects do not last long enough between doses.
16.5 Amantadine
Amantadine may help certain Parkinson’s symptoms and can be useful for some patients with levodopa-induced dyskinesia, which refers to involuntary movements associated with treatment.
Potential side effects include confusion, hallucinations, swelling, and skin changes.
The choice of formulation and dose depends on clinical circumstances, including kidney function.
16.6 Anticholinergic medicines
Certain anticholinergic medicines may reduce tremor in carefully selected patients.
However, they can cause memory problems, confusion, constipation, blurred vision, and urinary retention.
Because of these risks, they are generally avoided or used cautiously, especially in older adults and people with cognitive impairment.
16.7 Managing non-motor symptoms
Additional treatment may be needed for depression, anxiety, sleep problems, constipation, urinary symptoms, pain, and blood pressure changes.
The appropriate treatment depends on the cause of the symptom, other medications, and the individual's overall health.
Some medicines can worsen parkinsonism or interact with Parkinson’s treatments, so medication reviews are important.
17. Motor Fluctuations and Dyskinesia
As Parkinson’s disease progresses, some people experience changes in how reliably their medicines control symptoms.
17.1 Wearing-off
Wearing-off occurs when a medication's benefit fades before the next scheduled dose.
The person may notice that stiffness, slowness, tremor, or other symptoms return as the medicine's effect decreases.
Clinicians may adjust dose timing, formulations, or combinations of medicines to improve symptom control.
17.2 On-off fluctuations
Some people experience unpredictable changes between periods when movement is relatively easy and periods when symptoms become much more pronounced.
These fluctuations can interfere with work, travel, meals, and daily routines.
Treatment may require careful medication adjustment and, in selected patients, device-assisted therapies.
17.3 Dyskinesia
Dyskinesia refers to involuntary movements that may appear as twisting, writhing, fidgeting, or other uncontrolled movements.
It is often associated with long-term levodopa treatment, although not everyone develops it.
Clinicians balance symptom control against side effects and may consider dose adjustments, medication changes, amantadine, or advanced therapies when appropriate.
Patients should not make major medication changes independently.
18. Surgical and Device-Assisted Treatments
Some people continue to experience troublesome motor symptoms despite optimized medication. Selected patients may benefit from advanced treatment approaches.
18.1 Deep brain stimulation
Deep brain stimulation, or DBS, involves placing electrodes into specific brain regions involved in movement control.
The electrodes connect to a device that delivers electrical stimulation. The settings can be adjusted by the treating team.
DBS may improve tremor, rigidity, slowness, and medication-related motor fluctuations in appropriately selected patients.
It does not cure Parkinson’s disease, and it is not equally effective for every symptom. Balance problems, speech difficulties, cognitive impairment, and other non-motor symptoms may not improve and can sometimes worsen.
Candidates require careful evaluation of symptom patterns, medication response, cognitive function, mental health, and surgical risks.
18.2 Lesion-based procedures
Certain procedures target small areas of brain tissue involved in abnormal movement circuits.
Examples include pallidotomy and thalamotomy. Some procedures can be performed using focused ultrasound, which uses concentrated sound energy to create a targeted lesion.
These treatments may help selected symptoms, particularly certain forms of tremor, but their effects and risks differ from DBS.
Because lesion-based procedures create a permanent change in tissue, patient selection is important.
18.3 Infusion and other advanced therapies
Selected patients with advanced motor fluctuations may benefit from continuous delivery of Parkinson’s medication through specialized systems.
Options and eligibility depend on local availability, the specific device or medicine, the patient's needs, and specialist assessment.
These approaches aim to reduce fluctuations and improve daily functioning rather than cure the disease.
.jpeg)
